Study (Trail) | Publication Year | Study duration | Original nation | Median follow-up | No. of patient(n) | ER status | Primary endpoints | Chemotherapy strategy | Regimen |
---|---|---|---|---|---|---|---|---|---|
West [8] | 2011 | Unknow | Canada | Unknow | 111 | Negative | pCR | NAC | FEC or TET |
Seo [9] | 2013 | 2004–2011 | Korea | Unknow | 153 | Both | pCR | NAC | AC or ACT or AD |
Lee [10] | 2013 | 2000–2009 | Korea | Unknow | 175 | Both | pCR | NAC | AC or ACT |
Denkert [11]* | 2010 | 1999–2001 | Germany | Unknow | 218 | Both | pCR | NAC | ACT |
Denkert [11]* | 2010 | 2002–2005 | Germany | Unknow | 840 | Both | pCR | NAC | TAC or TAC followed by vinorelbine and capecitabine |
Denkert [12] | 2015 | Unknow | Germany | Unknow | 580 | Negative | pCR | Unknow | 1:1 to PM or PMCb |
Watanabe [13] | 2018 | 2008–2016 | Japan | 26.1 m | 197 | Both | pCR | NAC | Anthracycline- or taxane- or anthracycline- plus taxane-based |
Galvez [14] | 2018 | 2003–2014 | Peru | Unknow | 435 | Both | pCR | NAC | ACP or AC |
Hida [15] | 2016 | 2007–2014 | Japan | Unknow | 159 | Negative | pCR | NAC | Unknow |
Denkert [6] | 2018 | Unknow | Germany | Unknow | 3771 | Both | pCR, OS | NAC | Docetaxel- or paclitaxel- or nab-paclitaxel-based |
Hwang [16] | 2019 | 2004–2013 | Korea | 60.1 m | 248 | Both | pCR | NAC | Anthracycline- plus taxane-based |
Kim [17] | 2016 | 2004–2011 | Korea | 6.4y | 688 | Negative | OS | NAC | AC or ACT or ACP |
Sønderstrup [18] | 2019 | 1997–2011 | Denmark | 5.8y | 399 | Both | OS | Unknow | Unknow |
Pruneri [19] | 2016 | 1995–2010 | Switzerland | 8.2y | 897 | Negative | OS | AC | CMF, CMF + AC |
Pruneri [20] | 2016 | Unknow | Italy | 6.9y | 647 | Negative | OS | AC | 1:1 to CM or no-CM |
Tian [21] | 2016 | 2008–2012 | China | 4y | 372 | Negative | OS | AC | Anthracycline- or anthracycline- plus taxanes-based |
Adams [22] | 2014 | Unknow | USA | 10.6y | 481 | Negative | OS | NAC | ACT or ACP |
Loi [5] | 2014 | Unknow | Belgium | 62 m | 934 | Both | OS | NAC | Docetaxel or vinorelbine followed by FEC |
Kochi [23] | 2018 | Unknow | Japan | Unknow | 40 | Both | OS | NAC | Anthracycline- plus taxane-based |
Dieci [24] | 2015 | Unknow | France | 12.7y | 781 | Both | OS | AC | Anthracycline-based |
Luen [25] | 2019 | Unknow | Australia | 6y | 375 | Negative | OS | NAC | Unknow |
Luen [26] | 2017 | Unknow | Australia | 50 m | 678 | Negative | OS | AC | 1:1 to trastuzumab and docetaxel plus either pertuzumab or placebo |
Burugu [27] | 2017 | 1989–2002 | Canada | 13y | 2497 | Both | Others | AC | Unknow |